Leerink Partners has initiated coverage on Sensei Biotherapeutics (NASDAQ: SNSE) with an Outperform rating and a $50 price target, citing significant upside potential given the stock's current trading price of $30.49. The firm highlighted Sensei's oncology pipeline, particularly PIKTOR, a novel combination therapy, and noted the company's strong cash position relative to debt, although it is burning cash, typical for clinical-stage biotechs. Recent developments include the acquisition of Faeth Therapeutics and a $200 million private financing round.
Sensei Biotherapeutics announced an inducement grant to a new employee of an option to purchase 166,435 shares of common stock, effective March 11, 2026. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and involves an exercise price of $29.37, vesting over four years. Sensei Biotherapeutics is a clinical-stage biotechnology company focused on cancer therapeutics, with its lead program PIKTOR targeting endometrial and breast cancer.
BOSTON, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc. ( Nasdaq: SNSE ) , a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter 2025.
